Oncology News | pharmaphorum

News

Astellas gains three cancer drugs with $405m Potenza buy

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies.

News

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.

News

Closeup of X-ray photography of human brain

Certain brain tumours could respond to immunotherapy

Some brain tumours may respond to immunotherapy after all, according to a new study.

News

Gilead hires Roche's pharma chief Daniel O'Day as CEO

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced.

News

NICE gives final seal of approval for Gilead's CAR-T in NHL

NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

Astellas gains three cancer drugs with $405m Potenza buy

AZ begins liver cancer immunotherapy tie-up with AVEO

Certain brain tumours could respond to immunotherapy

Gilead hires Roche's pharma chief Daniel O'Day as CEO

NICE gives final seal of approval for Gilead's CAR-T in NHL

AZ's cancer drug fails again, Roche's rival gets new use

Antiviral development in the age of AI: From pre-IND to earl...

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks